Dianthus Therapeutics, Inc. Common Stock

DNTHNASDAQ • USD
ThemeBiotech - Drug Development›Immunology & Autoimmune
105.60 USD
↗ 10.25 (10.75%)AT CLOSE (11:59 AM EDT)
105.00
↘ 0.60 (0.57%)
POST MARKET (AS OF 06:51 PM EDT)
Post Market
AS OF 06:51 PM EDT
105.00
↘ 0.60 (0.57%)
🟢Market: OPEN

Dianthus Therapeutics, Inc. Common Stock (DNTH) trades at $100.29 per share. The stock presents a mixed profile: our models indicate a Strong Buy for technical indicators, while underlying fundamentals flash a Sell. Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 1/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Jul 17, 2026.

Open?$93.96
High?$105.72
Low?$91.01
Prev. Close?$95.35
Volume?1.0M
Avg. Volume?1.4M
VWAP?$102.35
Rel. Volume?0.74x
Bid / Ask
Bid?$77.99 × 100
Ask?$130.12 × 100
Spread?$52.13
Midpoint?$104.06
Valuation & Ratios
Market Cap?5.2B
Shares Out?54.7M
Float?51.2M
Float %?93.7%
P/E Ratio?N/A
P/B Ratio?4.34
EPS?-$3.18
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
Themes
Biotech - Drug Development›Immunology & Autoimmune
Employees
92
Market Cap
5.2B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.dianthustx.com
Listed
2023-09-12
Address
7 TIMES SQUARE
NEW YORK, NY 10036
Phone: 929-999-4055
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+1/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
100
Momentum?
23
Short Sent.?
21
Piotroski F-Score?1/9Weak
Altman Z-Score?68.74Safe
Confidence?55%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?18.62%High
Short Interest?9.5M
Days to Cover?5.5
Free Float51.2M
Avg Daily Volume1.7M
Settlement Date2026-06-30
Financial Health
Current Ratio?29.25Strong
Quick Ratio?29.25Strong
Cash Ratio?16.40Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
41
4.34FAIR▾
P/S?
Peers
100
S&P
3
3,901.52HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-24.0CHEAP▾
EV/Sales?
Peers
100
S&P
3
3,431.71HIGH▾
Returns & Efficiency
ROE?
S&P
9
-14.5%WEAK▾
ROA?
S&P
3
-13.9%WEAK▾
Cash Flow & Enterprise
FCF?$-130485000
Enterprise Value?$4.6B
Fundamentals ratios updated end of day
MarketsMoversWatchlist